Recent

% | $
Quotes you view appear here for quick access.

AbbVie Inc. Message Board

  • manumilitari_spqr manumilitari_spqr Jan 15, 2014 9:20 AM Flag

    AbbVie Announces Initiation of Pivotal Phase 3 Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer

    NORTH CHICAGO, Ill., Jan. 15, 2014 /PRNewswire/ -- AbbVie (ABBV) today announced the initiation of a Phase 3 clinical trial
    evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer. The three-arm trial will compare the addition of veliparib plus carboplatin or placebo plus carboplatin to standard neoadjuvant chemotherapy.

 
ABBV
59.77+0.47(+0.79%)9:30 AMEDT